AI Summary Cystic fibrosis (CF) is a genetic condition linked to CFTR gene mutations that make mucus hard to clear, affecting the lungs and nutrition. Some people also develop cystic fibrosis–associated liver disease, with signs such as jaundice and itching. Genetic testing and regular liver function tests guide care. CFTR modulators treat CF in people with eligible mutations but are not approved for liver disease, so daily care, good nutrition, and liver monitoring remain important.
Medically reviewed.
Cystic fibrosis (CF) is a genetic condition linked to mutations in the CFTR gene, which lead to a defective CFTR protein. This protein helps move chloride and water across the cells that line the body's surfaces. When it does not work well, mucus is harder to clear from the airways, and lung function and nutrition can be affected.
Some people with CF also develop liver disease, called cystic fibrosis–associated liver disease (CFLD). CFTR modulators are prescription medicines that treat the underlying protein defect in people with eligible mutations. They may also support liver health, but none is specifically approved to treat liver disease, so regular liver monitoring and routine CF care stay central.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
About cystic fibrosis
Cystic fibrosis (CF) is a genetic condition linked to mutations in the CFTR gene. These mutations lead to a defective CFTR protein, which normally helps move chloride and water across the cells that line the body's surfaces (epithelial cells).
When the CFTR protein does not work well, mucus does not stay hydrated and is harder to clear from the airways. This is why CF affects lung function and breathing, and why airway clearance is a routine part of care. CF can also affect nutritional status.
Some people with CF also develop liver disease. Doctors call this cystic fibrosis–associated liver disease (CFLD). Because liver disease can develop alongside CF, liver monitoring is part of care for people who take CFTR medicines.
CF is a lifelong condition. Treatment targets the underlying protein defect in people with eligible mutations and is often continued long term, alongside airway clearance, good nutrition, and infection prevention.
How cystic fibrosis may feel
Cystic fibrosis mostly affects the lungs and nutrition, and some people also develop liver disease. The signs below are grouped by the body system involved.
Getting checked
Cystic fibrosis care uses genetic testing to confirm eligibility for CFTR modulator therapy, and regular checks to follow liver health and treatment response.
Genetic testing confirms who is eligible for CFTR modulators, and regular liver function tests help your care team track liver health during treatment.
Care & management
Treatment for cystic fibrosis targets the underlying CFTR protein defect and supports daily health through airway clearance, nutrition, and regular monitoring. Treatment is long term, often lifelong.
CFTR modulators are prescription medicines that treat the underlying protein defect. Some help the defective CFTR protein reach the cell surface, and others help it open and work better. Trikafta, Orkambi, Symdeko, and Kalydeco are each used for people with eligible CFTR mutations. Your care team decides which option fits, based on genetic testing and health history.
Improving the CFTR defect may also support liver health in people with CFLD. However, Trikafta, Orkambi, Symdeko, and Kalydeco are not specifically approved or indicated to treat liver disease. Regular liver function tests are recommended during treatment.
Treatment works best alongside daily CF care: airway clearance therapy, good hydration, adequate nutrition, infection prevention, avoiding smoke exposure, and regular exercise as tolerated. Several modulators are taken with fat-containing food to help the body absorb them. Follow your care team's instructions and do not stop a medicine without their advice.
CFTR modulators treat cystic fibrosis itself and are often continued long term. They are not specifically approved for liver disease, so liver monitoring remains part of care.
Cystic fibrosis is caused by changes in the CFTR gene, not by anything a person did. Understanding the genetic cause helps explain why treatment is matched to specific mutations.
Cystic fibrosis comes from CFTR gene mutations. Genetic testing identifies the mutation, which guides which CFTR modulator may be an option.
When to get checked
Liver disease can develop in people with cystic fibrosis, and medicines used for CF can raise liver enzymes. Knowing when to seek evaluation helps your care team act early.
Talk with a healthcare provider if you have cystic fibrosis and notice yellowing of the skin or eyes, itching, loss of appetite, unusual fatigue, or pain inside or under the right side of the rib cage. Also ask about liver testing if you are starting or taking a CFTR modulator.
CFTR modulators are long-term treatments, and elevated liver enzymes are a reported side effect. Regular liver function tests let your care team catch changes early and adjust care. Dosing may need adjusting in people with liver impairment.
A liver specialist can work alongside your CF care team to review your liver health and discuss whether a CFTR modulator fits your care plan. Eligibility depends on genetic testing and your health history.
Find doctors experienced in liver disease and connect with a specialist near you.
Eating & liver health
Diet supports cystic fibrosis treatment but does not replace it. Good nutrition is a routine part of CF care, and it also helps protect the liver.
Several CFTR modulators are taken with fat-containing food about every 12 hours, which helps the body absorb the medicine. Eating enough calories and keeping up with hydration are also part of standard CF nutrition advice.
People with advanced liver disease may need extra fat-soluble vitamins (A, D, E, and K) if a deficiency develops. Vitamin and mineral supplements can be harmful in excess, so take them only under a doctor's guidance. Avoid alcohol unless your healthcare provider advises otherwise.
Nutrition Habits to Discuss With Your Care Team
Common questions
Cystic fibrosis (CF) is a genetic condition linked to mutations in the CFTR gene. These mutations lead to a defective CFTR protein, which normally helps move chloride and water across the cells that line the body's surfaces. When the protein does not work well, mucus is harder to clear, which affects the airways, lung function, and nutrition. Some people with CF also develop liver disease. CF is a lifelong condition, and treatment focuses on the underlying protein defect along with daily care such as airway clearance, good nutrition, and infection prevention.
Yes. Patients with cystic fibrosis may develop liver disease, which doctors call cystic fibrosis–associated liver disease (CFLD). Because of this, liver health is part of CF care. Your care team may check liver function tests regularly, especially if you take a CFTR modulator, since elevated liver enzymes are a reported side effect of these medicines. If you notice yellowing of the skin or eyes, itching, loss of appetite, or pain under the right ribs, tell your healthcare provider promptly.
CFTR modulators are prescription medicines that treat the underlying protein defect in cystic fibrosis. Some help the defective CFTR protein reach the cell surface, and others help it open and work better. That improves chloride and water movement, thins mucus, and helps lung function. Trikafta, Orkambi, Symdeko, and Kalydeco are used for people with eligible CFTR mutations. Kalydeco is used for specific responsive mutations, and Orkambi is used for people with two copies of the F508del mutation. Genetic testing confirms which option you are eligible for.
No. Trikafta, Orkambi, Symdeko, and Kalydeco are not specifically approved or indicated to treat liver disease. They are used to treat cystic fibrosis itself. In people with CFLD, improving the underlying CFTR defect may also support liver health, but this is a possible added benefit, not an approved use. Your care team may still recommend liver monitoring and other care for your liver. A liver specialist can help you decide how these medicines fit into your overall plan.
Regular monitoring is recommended. For Trikafta, Orkambi, and Kalydeco, this includes liver function tests and an overall review of how well treatment is working. Children may also need eye exams, and Orkambi monitoring includes blood pressure and respiratory status. Elevated liver enzymes are a reported side effect, and dosing may be adjusted for people with liver impairment or who take certain other medicines. Report new symptoms to your care team, and do not change or stop a medicine on your own.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
